Sonoma Pharmaceuticals, Inc.
SNOA · NASDAQ
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Revenue | $14,288 | $12,735 | $13,272 | $12,628 |
| % Growth | 12.2% | -4% | 5.1% | – |
| Cost of Goods Sold | $8,823 | $7,990 | $8,795 | $8,635 |
| Gross Profit | $5,465 | $4,745 | $4,477 | $3,993 |
| % Margin | 38.2% | 37.3% | 33.7% | 31.6% |
| R&D Expenses | $1,814 | $1,871 | $207 | $125 |
| G&A Expenses | $7,171 | $0 | $0 | $0 |
| SG&A Expenses | $7,361 | $7,575 | $8,840 | $9,755 |
| Sales & Mktg Exp. | $190 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $9,175 | $9,446 | $9,047 | $9,880 |
| Operating Income | -$3,710 | -$4,701 | -$4,570 | -$5,887 |
| % Margin | -26% | -36.9% | -34.4% | -46.6% |
| Other Income/Exp. Net | $803 | -$330 | -$614 | $469 |
| Pre-Tax Income | -$2,907 | -$5,031 | -$5,184 | -$5,418 |
| Tax Expense | $550 | -$196 | -$33 | -$332 |
| Net Income | -$3,457 | -$4,835 | -$5,151 | -$5,086 |
| % Margin | -24.2% | -38% | -38.8% | -40.3% |
| EPS | -2.79 | -5.32 | -15.18 | -19.17 |
| % Growth | 47.6% | 65% | 20.8% | – |
| EPS Diluted | -2.79 | -5.32 | -15.18 | -19.17 |
| Weighted Avg Shares Out | 1,241 | 909 | 339 | 265 |
| Weighted Avg Shares Out Dil | 1,241 | 909 | 339 | 265 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $16 | $0 |
| Interest Expense | $0 | $0 | $0 | $10 |
| Depreciation & Amortization | $138 | $176 | $125 | $186 |
| EBITDA | -$3,572 | -$4,525 | -$4,445 | -$5,701 |
| % Margin | -25% | -35.5% | -33.5% | -45.1% |